Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation

Background: This study is the first to examine the association between plasma levels of brain-derived neurotrophic factor (BDNF) and the antisuicidal effects of repeated ketamine infusions in depressed patients with suicidal ideation. Methods: Fifty-seven depressed patients with suicidal ideation received six ketamine infusions (0.5 mg/kg) during a 12 days period. Suicidality was measured with the Scale for Suicidal Ideations (SSI-part 1), item 10 of the Montgomery–Åsberg Depression Rating Scale (MADRS), and item 3 of the Hamilton Depression Rating Scale (HAMD) at baseline, 1 day after the first infusion (1 day), 1 day after the sixth infusion (13 days), and at 2 weeks after the last infusion (26 days). Plasma levels of BDNF were measured by enzyme-linked immunosorbent assay at baseline, 13 days, and 26 days. Results: Overall, 46 (80.7%) depressed patients with suicidal ideation had an antisuicidal response at 13 days. Despite a significant reduction in suicidal symptoms over time, no changes in plasma levels of BDNF were found after ketamine treatment when compared with baseline. Correlation analysis showed that no significant association was observed between the plasma levels of BDNF and the changes in the severity of suicidal symptoms as measured by SSI-part 1, item 10 of the MADRS, or item 3 of the HAMD at 1 day, 13 days, and 26 days (all p < 0.05). Conclusion: Our results indicated that plasma levels of BDNF may not serve as a biomarker for determining the antisuicidal effects of six ketamine infusions in depressed patients with suicidal ideation.

Download Full-text

Plasma Exosomal Brain-Derived Neurotrophic Factor Correlated with the Postural Instability and Gait Disturbance–Related Motor Symptoms in Patients with Parkinson’s Disease

Diagnostics ◽

10.3390/diagnostics10090684 ◽

2020 ◽

Vol 10 (9) ◽

pp. 684

Author(s):

Chen Chih Chung ◽

Pai Hao Huang ◽

Lung Chan ◽

Jia-Hung Chen ◽

Li-Nien Chien ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Neurotrophic Factor ◽

Rating Scale ◽

Brain Derived Neurotrophic Factor ◽

Postural Instability ◽

Gait Disturbance ◽

Enzyme Linked Immunosorbent Assay ◽

Motor Symptoms ◽

Bdnf Level

Brain-derived neurotrophic factor (BDNF) is an essential neurotrophin, responsible for neuronal development, function, and survival. Assessments of peripheral blood BDNF in patients with Parkinson’s disease (PD) previously yielded inconsistent results. Plasma exosomes can carry BDNF, so this study investigated the role of plasma exosomal BDNF level as a biomarker of PD. A total of 114 patients with mild to moderate PD and 42 non-PD controls were recruited, and their clinical presentations were evaluated. Plasma exosomes were isolated with exoEasy Maxi Kits, and enzyme-linked immunosorbent assay was used to assess plasma exosomal BDNF levels. Statistical analysis was performed using SPSS version 19.0, and findings were considered significant at p < 0.05. The analysis revealed no significant differences in plasma exosomal BDNF levels between patients with PD and controls. Patients with PD with low plasma exosomal BDNF levels (in the lowest quartile) exhibited a significant association with daily activity dysfunction but not with cognition/mood or overall motor symptoms as assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS). Investigation of UPDRS part III subitems revealed that low plasma exosomal BDNF level was significantly associated with increased motor severity of postural instability and gait disturbance (PIGD)-associated symptoms (rising from a chair, gait, and postural stability) after adjustment for age and sex. In conclusion, although plasma exosomal BDNF level could not distinguish patients with PD from controls, the association with PIGD symptoms in patients with PD may indicate its potential role as a biomarker. Follow-up studies should investigate the association between plasma exosomal BDNF levels and changes in clinical symptoms.

Download Full-text

Expression of Selected Genes Involved in Neurogenesis in the Etiopathogenesis of Depressive Disorders

Journal of Personalized Medicine ◽

10.3390/jpm11030168 ◽

2021 ◽

Vol 11 (3) ◽

pp. 168

Author(s):

Katarzyna Bliźniewska-Kowalska ◽

Piotr Gałecki ◽

Janusz Szemraj ◽

Monika Talarowska

Keyword(s):

Gene Expression ◽

Neurotrophic Factor ◽

Depressive Disorders ◽

Rating Scale ◽

Enzyme Linked Immunosorbent Assay ◽

Control Group ◽

Mrna Levels ◽

Depressed Patients ◽

Gdnf Gene ◽

Glial Derived Neurotrophic Factor

(1) Background: The neurogenic theory suggests that impaired neurogenesis within the dentate gyrus of the hippocampus is one of the factors causing depression. Immunology also has an impact on neurotrophic factors. The aim of the study was to assess the importance of selected genes involved in the process of neurogenesis i.e., nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF) and neuron-restrictive silencer factor (REST gene) in the etiopathogenesis of depressive disorders. (2) Methods: A total of 189 subjects took part in the study (95 depressed patients, 94 healthy controls). Sociodemographic data were collected. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). RT-PCR was used to assess gene expression at the mRNA levels, while Enzyme-Linked Immunosorbent Assay (ELISA) was used to assess gene expression at the protein level. (3) Results: Expression of NGF, BDNF, REST genes is lower in depressed patients than in the control group, whereas the expression of GDNF gene is higher in patients with depressive disorders than in the group of healthy volunteers. (4) Conclusions: The expression of selected genes might serve as a biomarker of depression.

Download Full-text

Perbandingan Kadar Brain – Derived Neurotrophic Factor Pasien Psoriasis Vulgaris Dan Bukan Pasien Psoriasis Vulgaris

Media Dermato Venereologica Indonesiana ◽

10.33820/mdvi.v45i1.9 ◽

2019 ◽

Vol 45 (1) ◽

Author(s):

Muhammad Sjahrir ◽

Elmeida Effendy ◽

Irma D Roesyanto

Keyword(s):

Immunosorbent Assay ◽

Neurotrophic Factor ◽

Psoriasis Vulgaris ◽

Brain Derived Neurotrophic Factor ◽

Enzyme Linked Immunosorbent Assay

Psoriasis adalah penyakit inflamasi kronik pada kulit, dengan dugaan kuat akibat pengaruh genetik. Psoriasis memiliki karakteristik berupa gangguan pertumbuhan dan diferensiasi epidermis serta keterlibatan agen biokimiawi, imunologik, kelainan vaskular, dan sistem saraf. Keterlibatan sistem saraf pada psoriasis salah satunya diperankan oleh brain-derived neurotrophic factor (BDNF). BDNF telah dikenal luas berperan pada kondisi stres dan depresi, namun BDNF ternyata juga memilki peran menjaga homeostasis korneosit. Penelitian ini bertujuan untuk mengetahui perbedaan kadar BDNF dalam serum pasien psoriasis vulgaris dibandingkan dengan bukan pasien psoriasis vulgaris.Penelitian ini adalah penelitian analitik dengan desain potong lintang. Sebanyak 20 orang pasien psoriasis vulgaris (kasus) dan 20 orang bukan pasien psoriasis vulgaris (kontrol) ikut serta dalam penelitian ini. Pada seluruh subyek penelitian dilakukan pengambilan darah untuk dilakukan pemeriksaan kadar BDNF dalam serum dengan metode enzyme-linked immunosorbent assay (ELISA). Kadar BDNF serum yang diperoleh kemudian dinilai perbedaannya antara kelompok kasus dan kontrol dengan menggunakan uji-t independen.Hasil penelitian didapatkan kadar BDNF dalam serum pasien psoriasis vulgaris lebih rendah secara bermakna (852,99 ± 172,28 pg/ml) dibandingkan dengan bukan pasien psoriasis vulgaris (1202,37 ± 67,06 pg/ml) dengan nilai p<0,05. Penelitian ini menyimpulkan bahwa terdapat perbedaan yang bermakna antara kadar BDNF serum pasien dan bukan pasien psoriasis vulgaris. Kata Kunci: psoriasis vulgaris, brain-derived neurotrophic factor

Download Full-text

Methodological approach to brain-derived neurotrophic factor plasma levels in major depressed patients receiving duloxetine

Neurological Sciences ◽

10.1007/s10072-015-2095-3 ◽

2015 ◽

Vol 36 (6) ◽

pp. 1061-1062 ◽

Cited By ~ 1

Author(s):

Mehmet Agilli ◽

Fevzi Nuri Aydin

Keyword(s):

Neurotrophic Factor ◽

Plasma Levels ◽

Methodological Approach ◽

Brain Derived Neurotrophic Factor ◽

Depressed Patients

Download Full-text

Interaction effects of diabetes and brain-derived neurotrophic factor on suicidal ideation in patients with acute coronary syndrome

10.21203/rs.3.rs-326048/v1 ◽

2021 ◽

Author(s):

Wonsuk Choi ◽

Ju-Wan Kim ◽

Hee-Ju Kang ◽

Hee Kyung Kim ◽

Ho-Cheol Kang ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Suicidal Ideation ◽

Neurotrophic Factor ◽

Rating Scale ◽

Brain Derived Neurotrophic Factor ◽

Interaction Effects ◽

Diabetic Patients ◽

Val66met Polymorphism ◽

Coronary Syndrome ◽

Increased Risk

Abstract Background Acute coronary syndrome (ACS) is associated with an increased risk of suicide. Although both diabetes and the brain-derived neurotrophic factor (BDNF) pathway are closely related to ACS and suicide, the effects of these factors on suicidal behavior in ACS patients have not been assessed. The aim of this study was to investigate the individual and interaction effects of diabetes and BDNF-related markers, namely the serum BDNF (sBDNF) level and the BDNF Val66Met polymorphism, on suicidal ideation (SI) in ACS patients. Methods The presence of diabetes was ascertained, and sBDNF levels and the presence of the BDNF Val66Met polymorphism were measured in 969 patients within 2 weeks after an ACS episode. Among these patients, 711 were followed up at 1 year after the ACS episode. SI was evaluated using the relevant items of the Montgomery–Åsberg Depression Rating Scale at baseline (acute SI) and the 1-year follow-up (chronic SI). Results Significant individual effects of low sBDNF levels were found on acute SI. The presence of both diabetes and a low sBDNF level or the BDNF Met/Met genotype was associated with acute SI, with multivariate logistic regression analyses revealing significant interaction effects. The highest frequency of chronic SI was seen in diabetic patients with an sBDNF level in the lowest tertile or with the BDNF Met/Met genotype, although the interaction terms were not statistically significant. Conclusions Combining diabetes and BDNF-related markers, such as the sBDNF level and the BDNF Val66Met polymorphism, might provide a useful predictor of acute SI in patients with ACS.

Download Full-text

Antidepressant treatment restores brain-derived neurotrophic factor (BDNF) serum levels and ameliorates motor function in parkinson's disease patients

European Psychiatry ◽

10.1016/s0924-9338(11)72190-3 ◽

2011 ◽

Vol 26 (S2) ◽

pp. 483-483

Author(s):

V. Ricci ◽

M. Pomponi ◽

G. Martinotti ◽

A. Bentivoglio ◽

G. Loria ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Neurotrophic Factor ◽

Antidepressant Drugs ◽

Serum Levels ◽

Brain Derived Neurotrophic Factor ◽

Antidepressant Therapy ◽

Enzyme Linked Immunosorbent Assay ◽

List Type ◽

Depressed Patients

IntroductionDepression is a common psychiatric disorder in Parkinson's disease (PD). It has been proposed that antidepressant drugs may bust brain production of trophic factors, such as brain-derived neurotrophic factor (BDNF) and glial cell derived neurotrophic factor (GDNF), an effect associated with improvement of clinical symptoms. However, BDNF and GDNF play also a role in the maintenance of dopaminergic neurons, which undergo to neuronal death during PD course.AimsBased on these findings we explored the hypothesis that PD depressed patients may have altered BDNF or GDNF serum levels and that antidepressant drugs may restore them and potentially have beneficial effects not only for depressive but also parkinsonian symptoms.MethodsWe measured by enzyme linked immunosorbent assay (ELISA) the serum levels of BDNF and GDNF in depressed PD patients, non depressed PD patients and healthy subjects and correlated them with clinical observations.ResultsWe found:(1)BDNF serum levels were decreased in PD depressed as compared to non depressed patients and control subjects;(2)antidepressant therapy restored BDNF serum levels to those of controls; and(3)antidepressant therapy in association with Parkinson's therapy significantly ameliorated motor performance in PD depressed patients.ConclusionOur data suggest that PD patients are characterized by a reduction of BDNF serum levels and that depression may exacerbate this effect and worse PD symptoms. It is proposed that association between anti-parkinsonian treatment and SSRI could be a good therapeutic chance not only for treating depression in PD but also for improving PD symptoms.

Download Full-text